Close

Clinical Trials

Roche reports promising Phase II results with new targeted...

Roche announced results from a Phase II clinical study of RG7204 PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of...

Genzyme Announces Results of Phase 3 Trial of Clolar...

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine...

Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill...

Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the...

Amgen announced that results from the PRIME ‘203’ and...

Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as...

Bristol-Myers Squibb announced results from a randomized, double-blind Phase...

Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read